{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:55:29Z","timestamp":1783468529478,"version":"3.55.0"},"reference-count":27,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,11,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Renal injury is a common complication of multiple myeloma (MM) and is associated with adverse outcome. Despite this, the natural history of renal injury in patients with MM remains uncertain especially in the context of intensive therapy and novel therapies. To address the lack of data, we evaluated the renal function of 2334 patients from the UK National Cancer Research Institute Myeloma XI trial at baseline and at 12 months to assess renal function over time and the factors associated with change. Patients who had severe acute kidney injury or a requirement for dialysis were excluded. At 12 months of the 1450 evaluable patients planned for autologous transplantation; 204 (14%) patients had a decline in estimated glomerular filtration rate (eGFR) \u226525% from baseline, 341 (23.5%) had an improvement and 905 (62%) had no significant change in eGFR. Renal outcome at 12 months for the 884 evaluable patients who were not planned for transplant was similar. Improved renal function was more likely if patients were &amp;lt;70 years old, male, had an average eGFR &amp;lt;60 mL per minute per 1.73 m2 and a higher baseline free light chain level &amp;gt;1000 mg\/L, and\/or a free light chain response of &amp;gt;90%. It did not correlate with monoclonal\u2013protein response, transplantation, or use of a bortezomib-based regimen. We show that with current therapies the proportion of patients who have a significant decline in renal function in the first 12 months is small. The greatest relative improvement in eGFR is seen in patients with high free light chain at baseline and a high light chain response. This trial was registered at http:\/\/www.isrctn.com as #49407852.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020002872","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T20:58:15Z","timestamp":1607029095000},"page":"5836-5845","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Renal outcome in patients with newly diagnosed multiple myeloma: results from the UK NCRI Myeloma XI trial"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3570-3959","authenticated-orcid":false,"given":"Ritika","family":"Rana","sequence":"first","affiliation":[{"name":"Department of Renal Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom;"},{"name":"Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cockwell","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Drayson","sequence":"additional","affiliation":[{"name":"Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8647-9208","authenticated-orcid":false,"given":"Mark","family":"Cook","sequence":"additional","affiliation":[{"name":"Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Pratt","sequence":"additional","affiliation":[{"name":"Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2338-0179","authenticated-orcid":false,"given":"David A.","family":"Cairns","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, University of Leeds, Leeds, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Pawlyn","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Jackson","sequence":"additional","affiliation":[{"name":"Department of Haematology, University of Newcastle, Newcastle-upon-Tyne, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith","family":"Davies","sequence":"additional","affiliation":[{"name":"Perlmutter Cancer Center, NYU Langone Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Morgan","sequence":"additional","affiliation":[{"name":"Perlmutter Cancer Center, NYU Langone Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Helen","family":"Pinney","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom;"},{"name":"Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,11,24]]},"reference":[{"issue":"17","key":"2020120315422650700_B1","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","article-title":"Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution","volume":"158","author":"Blad\u00e9","year":"1998","journal-title":"Arch Intern Med"},{"issue":"4","key":"2020120315422650700_B2","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1365-2141.1995.tb05400.x","article-title":"Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases","volume":"91","author":"Torra","year":"1995","journal-title":"Br J Haematol"},{"issue":"36","key":"2020120315422650700_B3","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002\u2013Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020120315422650700_B4","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ajh.24335","article-title":"Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis","volume":"91","author":"Dimopoulos","year":"2016","journal-title":"Am J Hematol"},{"issue":"6","key":"2020120315422650700_B5","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1681\/ASN.2010080857","article-title":"Early reduction of serum-free light chains associates with renal recovery in myeloma kidney","volume":"22","author":"Hutchison","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2020120315422650700_B6","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2215\/CJN.04590908","article-title":"Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis","volume":"4","author":"Hutchison","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"21","key":"2020120315422650700_B7","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2017.17924","article-title":"Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: a randomized clinical trial","volume":"318","author":"Bridoux","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"2020120315422650700_B8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"2020120315422650700_B9","doi-asserted-by":"crossref","first-page":"e616","DOI":"10.1016\/S2352-3026(19)30167-X","article-title":"Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"6","author":"Jackson","year":"2019","journal-title":"Lancet Haematol"},{"key":"2020120315422650700_B10","article-title":"Lenalidomide before and after ASCT for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial [published online ahead of print 4 June 2020]","author":"Jackson","journal-title":"Haematologica"},{"key":"2020120315422650700_B11","first-page":"136","article-title":"KDIGO 2012 Clinical Practice Guideline for the evaluation and management of chronic kidney disease","volume-title":"Kidney Int Suppl","author":"Kidney Disease: Improving Global Outcomes","year":"2013"},{"key":"2020120315422650700_B12","article-title":"The UK eCKD guide","author":"Renal Association"},{"issue":"2","key":"2020120315422650700_B13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume":"23","author":"Dispenzieri","year":"2009","journal-title":"Leukemia"},{"issue":"9","key":"2020120315422650700_B14","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma [published errata appear in Leukemia. 2006;20(12)2220 and Leukemia. 2007;21(5):1134]","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"1","key":"2020120315422650700_B15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13063-018-3108-3","article-title":"The correlation between baseline score and post-intervention score, and its implications for statistical analysis","volume":"20","author":"Clifton","year":"2019","journal-title":"Trials"},{"issue":"1","key":"2020120315422650700_B16","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12882-018-0962-x","article-title":"Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma","volume":"19","author":"Yadav","year":"2018","journal-title":"BMC Nephrol"},{"issue":"1","key":"2020120315422650700_B17","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1186\/s12885-018-4926-0","article-title":"Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study","volume":"18","author":"Antlanger","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"2020120315422650700_B18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2369-9-11","article-title":"Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure","volume":"9","author":"Hutchison","year":"2008","journal-title":"BMC Nephrol"},{"issue":"4","key":"2020120315422650700_B19","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/ki.2014.333","article-title":"The use of immunoglobulin light chain assays in the diagnosis of paraprotein-related kidney disease","volume":"87","author":"Yadav","year":"2015","journal-title":"Kidney Int"},{"issue":"4","key":"2020120315422650700_B20","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(19)30014-6","article-title":"High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial","volume":"6","author":"Hutchison","year":"2019","journal-title":"Lancet Haematol"},{"issue":"10","key":"2020120315422650700_B21","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1136\/jcp.2010.079236","article-title":"Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney","volume":"63","author":"Basnayake","year":"2010","journal-title":"J Clin Pathol"},{"issue":"8","key":"2020120315422650700_B22","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1158\/1055-9965.EPI-11-0157","article-title":"Gender disparities in the tumor genetics and clinical outcome of multiple myeloma","volume":"20","author":"Boyd","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"33","key":"2020120315422650700_B23","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","article-title":"Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group","volume":"28","author":"Dimopoulos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020120315422650700_B24","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3324\/haematol.2014.115204","article-title":"Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study","volume":"100","author":"Ludwig","year":"2015","journal-title":"Haematologica"},{"issue":"11","key":"2020120315422650700_B25","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00432-013-1513-2","article-title":"Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure","volume":"139","author":"P\u00f6nisch","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"2020120315422650700_B26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/leu.2012.182","article-title":"The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma","volume":"27","author":"Dimopoulos","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"2020120315422650700_B27","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3816\/CLM.2009.n.059","article-title":"Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors","volume":"9","author":"Dimopoulos","year":"2009","journal-title":"Clin Lymphoma Myeloma"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/22\/5836\/1790750\/advancesadv2020002872.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/22\/5836\/1790750\/advancesadv2020002872.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T20:58:26Z","timestamp":1607029106000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/22\/5836\/474236\/Renal-outcome-in-patients-with-newly-diagnosed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,24]]},"references-count":27,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2020,11,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020002872","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,24]]}}}